# Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

> **NCT00138229** · PHASE2 · TERMINATED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 6 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00138229
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2012-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138229, "Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00138229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*